KR102122618B1 - 인플루엔자 중화를 위한 작용제 - Google Patents

인플루엔자 중화를 위한 작용제 Download PDF

Info

Publication number
KR102122618B1
KR102122618B1 KR1020147034586A KR20147034586A KR102122618B1 KR 102122618 B1 KR102122618 B1 KR 102122618B1 KR 1020147034586 A KR1020147034586 A KR 1020147034586A KR 20147034586 A KR20147034586 A KR 20147034586A KR 102122618 B1 KR102122618 B1 KR 102122618B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
influenza
gly
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147034586A
Other languages
English (en)
Korean (ko)
Other versions
KR20150008180A (ko
Inventor
에스. 라구람
비스와나탄 사시세크하란
벤카타라마난 사운다라라잔
람 사시세크하란
비드야 수브라마니안
칸난 타라카라만
Original Assignee
메사츄세츠 인스티튜트 어브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메사츄세츠 인스티튜트 어브 테크놀로지 filed Critical 메사츄세츠 인스티튜트 어브 테크놀로지
Publication of KR20150008180A publication Critical patent/KR20150008180A/ko
Application granted granted Critical
Publication of KR102122618B1 publication Critical patent/KR102122618B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147034586A 2012-05-10 2013-03-14 인플루엔자 중화를 위한 작용제 Active KR102122618B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645453P 2012-05-10 2012-05-10
US61/645,453 2012-05-10
PCT/US2013/031704 WO2013169377A1 (en) 2012-05-10 2013-03-14 Agents for influenza neutralization

Publications (2)

Publication Number Publication Date
KR20150008180A KR20150008180A (ko) 2015-01-21
KR102122618B1 true KR102122618B1 (ko) 2020-06-29

Family

ID=49548780

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147034586A Active KR102122618B1 (ko) 2012-05-10 2013-03-14 인플루엔자 중화를 위한 작용제

Country Status (14)

Country Link
US (4) US9683030B2 (enExample)
EP (2) EP2846833A4 (enExample)
JP (2) JP6431477B2 (enExample)
KR (1) KR102122618B1 (enExample)
CN (2) CN109265541A (enExample)
AU (2) AU2013260123A1 (enExample)
BR (1) BR112014027991A2 (enExample)
CA (1) CA2871160C (enExample)
CL (1) CL2014003052A1 (enExample)
HK (1) HK1207970A1 (enExample)
IL (1) IL235237A0 (enExample)
MX (1) MX378749B (enExample)
SG (2) SG10201807059QA (enExample)
WO (1) WO2013169377A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683030B2 (en) 2012-05-10 2017-06-20 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EA038407B1 (ru) 2015-02-05 2021-08-24 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
BR112017024206A2 (pt) * 2015-05-11 2018-07-17 Janssen Vaccines & Prevention Bv compostos peptidomiméticos neutralizadores do vírus da gripe
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
KR101887876B1 (ko) 2016-08-18 2018-08-13 한국과학기술연구원 H5형 조류독감 바이러스에 특이적으로 결합하는 핵산 압타머 및 이를 이용하는 h5형 조류독감 바이러스의 검출방법
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021119467A1 (en) 2019-12-11 2021-06-17 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL23522C (enExample) 1927-03-23
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JPH06247995A (ja) 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
JP3584990B2 (ja) * 1994-05-09 2004-11-04 タカラバイオ株式会社 抗ヒトインフルエンザウイルス抗体
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
WO2000059932A1 (fr) 1999-03-31 2000-10-12 Otsuka Pharmaceutical Co., Ltd. Peptides se liant a l'hemagglutinine du virus de la grippe
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CN1639199A (zh) 2002-03-04 2005-07-13 独立行政法人科学技术振兴机构 新型支链状唾液糖分子与使用该糖分子的抗病毒剂
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
EP1573047B1 (en) 2002-08-20 2013-11-13 OpSaniTx LLC Lectin compositions and methods for modulating an immune response to an antigen
AU2005303817B8 (en) 2004-11-11 2010-09-30 Abbott Biologicals B.V. Defective influenza virus particles
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CN104803865A (zh) 2004-12-22 2015-07-29 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
CN101553502A (zh) 2006-08-14 2009-10-07 麻省理工学院 血球凝集素多肽和其相关试剂和方法
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2008021415A2 (en) 2006-08-14 2008-02-21 Massachusetts Institute Of Technology Glycan data mining system
BRPI0813922A2 (pt) * 2007-06-25 2017-05-09 Autoimmune Tech Llc composições de inibição de influenza e métodos.
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009089121A2 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
RU2553325C2 (ru) 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
JP6210685B2 (ja) 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
JP2013531474A (ja) * 2010-04-30 2013-08-08 エスペランス ファーマシューティカルズ， インコーポレイテッド 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法
SG10201709806VA (en) * 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9683030B2 (en) 2012-05-10 2017-06-20 Massachusetts Institute Of Technology Agents for influenza neutralization
JP6247995B2 (ja) 2014-04-22 2017-12-13 東京エレクトロン株式会社 接合方法、プログラム、コンピュータ記憶媒体、接合装置及び接合システム

Also Published As

Publication number Publication date
AU2018202468A1 (en) 2018-04-26
US20170306003A1 (en) 2017-10-26
SG11201406769RA (en) 2014-11-27
US20130302348A1 (en) 2013-11-14
CL2014003052A1 (es) 2015-06-26
AU2013260123A1 (en) 2014-11-13
CA2871160A1 (en) 2013-11-14
US9982037B2 (en) 2018-05-29
US10538578B2 (en) 2020-01-21
MX2014013678A (es) 2015-02-04
US20200123234A1 (en) 2020-04-23
EP3492101A3 (en) 2019-10-23
US9683030B2 (en) 2017-06-20
KR20150008180A (ko) 2015-01-21
CN104507500A (zh) 2015-04-08
IL235237A0 (en) 2014-12-31
CN109265541A (zh) 2019-01-25
JP6431477B2 (ja) 2018-12-05
CA2871160C (en) 2023-03-14
SG10201807059QA (en) 2018-09-27
EP2846833A1 (en) 2015-03-18
WO2013169377A1 (en) 2013-11-14
HK1207970A1 (en) 2016-02-19
US10947300B2 (en) 2021-03-16
US20190062407A1 (en) 2019-02-28
BR112014027991A2 (pt) 2017-07-18
EP3492101A2 (en) 2019-06-05
JP2015517492A (ja) 2015-06-22
JP2018118991A (ja) 2018-08-02
EP2846833A4 (en) 2016-01-06
MX378749B (es) 2025-03-10
AU2018202468B2 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
KR102122618B1 (ko) 인플루엔자 중화를 위한 작용제
CA2790949C (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
US10800835B2 (en) HA binding agents
US9475861B2 (en) Binding molecule having influenza A virus-neutralizing activity produced from human B cell
US10519220B2 (en) Full spectrum anti-dengue antibody
ES2802623T3 (es) Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe
US10526375B2 (en) Human Adaptation of H7 HA
US9834594B2 (en) Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141209

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180307

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190619

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191217

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200414

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200608

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200608

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240523

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250522

Start annual number: 6

End annual number: 6